Synergy Pharmaceuticals Inc (NASDAQ:SGYP)
Synergy Pharmaceuticals investors are grinning from ear to ear today as the company’s stock continues its incredible day in the market. Today, the stock is up by more than 10% from the previous close and looks to be headed for more gains. So today, we’ll talk about the billionaire stake in the company that caused the climb, take a look at what we’re seeing in the market right now, and talk about what we can expect to see from SGYP moving forward. So, lets get right to it.
Paulson & Co. Pushes SGYP Higher
John Paulson is the owner of the Paulson & co. hedge fund; which disclosed that it had added 2,095,600 shares of SGYP to its investment portfolio throughout the first quarter of 2015. The news was disclosed Friday after hours in a Securities and Exchange Commission regulatory filing and represents the fact that the Paulson & Co. hedge fund now owns a 2.11% stake in the company. As a result of the news, investors and traders alike reacted; pushing the stock higher.
What We’re Seeing From Synergy Pharmaceuticals In The Market Today
As mentioned above, Synergy Pharmaceuticals is having a great day in the market today. After a slight dip from highs in morning trading, the stock continued back on the upward path. Currently (12:04), SGYP is trading at $0.42 per share after a gain of 11.93% so far today.
What We Can Expect To See From SGYP Moving Forward
When it comes to Synergy Pharmaceuticals stock, I’m expecting to see growth in both the short and long term. Here’s why…
- Short Term Outlook – In the short term, I think we’re likely to see a slight correction from current highs. This is purely because of the fact that price movements in the market are a series of overreactions. With that said, we’re likely to see a slight correction followed by more short term gains.
- Long Term Outlook – When it comes to the long term, things get a bit more detailed. Synergy Pharmaceuticals is a clinical stage biopharmaceutical company with a focus on a key gastrointestinal hormone naturally found in the body that regulates digestive functioning. This hormone is called uroguanylin. The scientists at SGYP have discovered and developed two analogs of uroguanylin that are designed to mirror the natural hormone’s activity and target a variety of gastrointestinal conditions. When it comes tot he company’s pipeline, you’ll find that there is a compelling list of candidates. Not to mention, the company’s management seems to be solid; with a core focus on the development and commercialization of their treatments. All in all, SGYP seems fundamentally sound to me; so, we should see long-run gains from the stock.